7月17日，安进盘中上涨3.03%，报369.17美元/股，成交额2.85亿美元。
消息面上，近日多家投行密集上调安进目标价：瑞银将目标价从400美元上调至420美元并维持买入评级，美银证券将目标价从307美元上调至312美元，Truist Securities亦将目标价从327美元上调至340美元。当前分析师一致目标均价为357.04美元，整体评级为"增持"。此外，摩根士丹利指出下半年生物制药板块将更多由公司基本面驱动，安进多元化业务布局及新兴管线获市场积极评价。同行业中，艾伯维涨3.4%、吉利德涨2.37%，板块整体表现强势。
安进公司成立于1980年，是全球领先的独立生物技术公司之一，专注于发现、开发和交付创新药物，覆盖心脏代谢、肿瘤、罕见病等高度未满足医疗需求领域。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.